Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Breast Cancer Res Treat
2012 Apr 01;1323:1001-8. doi: 10.1007/s10549-011-1675-z.
Show Gene links
Show Anatomy links
Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2.
Ma X
,
Kundu N
,
Collin PD
,
Goloubeva O
,
Fulton AM
.
???displayArticle.abstract???
Frondoside A, derived from the sea cucumber Cucumaria frondosa has demonstrable anticancer activity in several models, however, the ability of Frondoside A to affect tumor metastasis has not been reported. Using a syngeneic murine model of metastatic breast cancer, we now show that Frondoside A has potent antimetastatic activity. Frondoside A given i.p. to mice bearing mammary gland-implanted mammary tumors, inhibits spontaneous tumor metastasis to the lungs. The elevated Cyclooxygenase-2 activity in many malignancies promotes tumor growth and metastasis by producing high levels of PGE(2) which acts on the prostaglandin E receptors, chiefly EP4 and EP2. We examined the ability of Frondoside A to modulate the functions of these EP receptors. We now show that Frondoside A antagonizes the prostaglandin E receptors EP2 and EP4. (3)H-PGE(2) binding to recombinant EP2 or EP4-expressing cells was inhibited by Frondoside A at low μM concentrations. Likewise, EP4 or EP2-linked activation of intracellular cAMP as well as EP4-mediated ERK1/2 activation were also inhibited by Frondoside A. Consistent with the antimetastatic activity observed in vivo, migration of tumor cells in vitro in response to EP4 or EP2 agonists was also inhibited by Frondoside A. These studies identify a new function for an agent with known antitumor activity, and show that the antimetastatic activity may be due in part to a novel mechanism of action. These studies add to the growing body of evidence that Frondoside A may be a promising new agent with potential to treat cancer and may also represent a potential new modality to antagonize EP4.
Al Marzouqi,
Frondoside A inhibits human breast cancer cell survival, migration, invasion and the growth of breast tumor xenografts.
2011, Pubmed,
Echinobase
Al Marzouqi,
Frondoside A inhibits human breast cancer cell survival, migration, invasion and the growth of breast tumor xenografts.
2011,
Pubmed
,
Echinobase
Aminin,
Immunomodulatory properties of frondoside A, a major triterpene glycoside from the North Atlantic commercially harvested sea cucumber Cucumaria frondosa.
2008,
Pubmed
,
Echinobase
Davis,
Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor.
2000,
Pubmed
Fulton,
Relationships of prostaglandin E and natural killer sensitivity to metastatic potential in murine mammary adenocarcinomas.
1985,
Pubmed
Holt,
Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4.
2011,
Pubmed
Janakiram,
Chemopreventive effects of Frondanol A5, a Cucumaria frondosa extract, against rat colon carcinogenesis and inhibition of human colon cancer cell growth.
2010,
Pubmed
,
Echinobase
Kundu,
Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer.
2002,
Pubmed
Kundu,
Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle.
2002,
Pubmed
Kundu,
Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function.
2009,
Pubmed
Lee,
Selective inhibition of prostaglandin E2 receptors EP2 and EP4 inhibits invasion of human immortalized endometriotic epithelial and stromal cells through suppression of metalloproteinases.
2011,
Pubmed
Li,
Review of the apoptosis pathways in pancreatic cancer and the anti-apoptotic effects of the novel sea cucumber compound, Frondoside A.
2008,
Pubmed
,
Echinobase
Ma,
Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis.
2006,
Pubmed
Narumiya,
Prostanoids in immunity: roles revealed by mice deficient in their receptors.
2003,
Pubmed
Narumiya,
Prostanoid receptors: structures, properties, and functions.
1999,
Pubmed
Rao,
Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo.
2007,
Pubmed
Ristimäki,
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.
2002,
Pubmed
Robertson,
Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4.
2010,
Pubmed
Roginsky,
Anti-pancreatic cancer effects of a polar extract from the edible sea cucumber, Cucumaria frondosa.
2010,
Pubmed
,
Echinobase
Sinha,
Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.
2007,
Pubmed
Timoshenko,
Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells.
2003,
Pubmed
Wang,
Eicosanoids and cancer.
2010,
Pubmed
Yang,
Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism.
2006,
Pubmed
